These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 18240162

  • 1. Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models.
    Zambon A, Baio G, Mazzaglia G, Merlino L, Corrao G.
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):260-9. PubMed ID: 18240162
    [Abstract] [Full Text] [Related]

  • 2. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA, Amonkar MM, Hebborn A, Altman R.
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [Abstract] [Full Text] [Related]

  • 3. Loss of treatment benefit due to low compliance with bisphosphonate therapy.
    Penning-van Beest FJ, Erkens JA, Olson M, Herings RM.
    Osteoporos Int; 2008 Apr; 19(4):511-7. PubMed ID: 17874028
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
    Gold DT, Martin BC, Frytak JR, Amonkar MM, Cosman F.
    Curr Med Res Opin; 2007 Mar; 23(3):585-94. PubMed ID: 17355739
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H.
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [Abstract] [Full Text] [Related]

  • 7. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD, Hanley DA, Lorraine JK, Yu M.
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Factors contributing to compliance with osteoporosis medication.
    Kertes J, Dushenat M, Vesterman JL, Lemberger J, Bregman J, Friedman N.
    Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
    Danese MD, Badamgarav E, Bauer DC.
    J Bone Miner Res; 2009 Nov; 24(11):1819-26. PubMed ID: 19419313
    [Abstract] [Full Text] [Related]

  • 13. Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO).
    Jakob F, Marín F, Martín-Mola E, Torgerson D, Fardellone P, Adami S, Thalassinos NC, Sykes D, Melo-Gomes J, Chinn C, Nicholson T, Cooper C.
    QJM; 2006 Aug; 99(8):531-43. PubMed ID: 16861718
    [Abstract] [Full Text] [Related]

  • 14. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB.
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
    Cramer JA, Silverman S.
    Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
    [Abstract] [Full Text] [Related]

  • 18. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T, Sugimoto T.
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [Abstract] [Full Text] [Related]

  • 19. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
    Lu PY, Hsieh CF, Tsai YW, Huang WF.
    Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
    [Abstract] [Full Text] [Related]

  • 20. Atrial fibrillation in fracture patients treated with oral bisphosphonates.
    Abrahamsen B, Eiken P, Brixen K.
    J Intern Med; 2009 May; 265(5):581-92. PubMed ID: 19141097
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.